Abstract
The article explores the preventive measures for West Nile disease, starting with the origin of West Nile virus, first introducing the main processes of vaccine development, describing the two main types of vaccines: equine and human vaccines, citing research data showing the success of equine vaccine development, exposing the progress of human vaccine research, the possible problems, to whether there are studies confirming the breakthrough of this problem. The examples of two live attenuated vaccines are used to show the progress of vaccine development at this stage, and the problems and possible solutions to the vaccine are analyzed in light of its cost-effectiveness. Other preventive measures that are available to achieve the preventive effect are further analyzed, which are divided into two categories, the first being regional level protective measures by interfering with the transmission route, and the second being individual level protective measures by reducing contact with the source of transmission. The study data confirmed the need to maintain and strengthen bird monitoring programs, and ranked regional and personal precautions, analyzing the problems with regional precautions and the need for problem-specific ranking.
Publisher
Darcy & Roy Press Co. Ltd.
Reference13 articles.
1. West Nile virus https://www.who.int/news-room/fact-sheets/detail/west-nile-virus.
2. West Nile Virus Vaccines https://www.niaid.nih.gov/diseases-conditions/wnv-vaccines.
3. García-Bocanegra I, Franco JJ, León CI, Barbero-Moyano J, García-Miña MV, Fernández-Molera V, Gómez MB, Cano-Terriza D, Gonzálvez M. High exposure of West Nile virus in equid and wild bird populations in Spain following the epidemic outbreak in 2020. Transbound Emerg Dis. 2022 Oct 12.
4. H ow are vaccines developed? https://www.who.int/zh/news-room/feature-stories/detail/how-are-vaccines-developed.
5. Samina I, Khinich Y, Simanov M, Malkinson M. An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine. 2005 Sep 30;23(41):4955-8.